About this Research Topic
Fatigue, pain, cognitive impairments, and dermatological and sleep issues are hallmark symptoms associated with gadolinium exposure. As a rare earth metal, gadolinium possesses unique properties that enhance magnetic resonance imaging (MRI) signals at low concentrations. However, it is important to recognize that gadolinium is inherently toxic and not naturally occurring in the body. An alarming phenomenon observed in all patients exposed to MRI contrast agents, regardless of the brand, is the retention of gadolinium in vital organs, including the brain.
Understanding the biological and long-term clinical effects of rare earth metals and nanoparticles has become an urgent priority. This Research Topic aims to delve deep into the complexities of gadolinium toxicity, shedding light on current knowledge while addressing the gaps that persist. We present a compelling case report documenting the chronic complications arising from exposure to MRI contrast agents, along with the subsequent alleviation of symptoms as gadolinium was purged from the patient's system. As strong advocates of patient safety, we are deeply concerned about the safety profiles of MRI contrast agents, particularly their potential ecotoxicological implications when predominantly eliminated through urination. Furthermore, our evidence uncovers the possibility that ordinary human metabolites may destabilize MRI contrast agents, amplifying the need for further investigation.
Crucially, our findings reveal a correlation between gadolinium retention and intracellular gadolinium-rich nanoparticles. This discovery paves the way for a fundamental understanding of the underlying mechanisms, necessitating rigorous investigation to inform and develop effective therapeutic interventions for patients with rare earth metal-induced illnesses, be they iatrogenic or environmentally induced. By unraveling the mysteries of gadolinium toxicity, we strive to contribute to the future development of rational therapies that prioritize patient well-being and safety.
Understanding the biological and long-term clinical effects of rare earth metals and nanoparticles has become an urgent priority. This Research Topic aims to delve deep into the complexities of gadolinium toxicity, shedding light on current knowledge while addressing the gaps that persist. We present a compelling case report documenting the chronic complications arising from exposure to MRI contrast agents, along with the subsequent alleviation of symptoms as gadolinium was purged from the patient's system. As strong advocates of patient safety, we are deeply concerned about the safety profiles of MRI contrast agents, particularly their potential ecotoxicological implications when predominantly eliminated through urination. Furthermore, our evidence uncovers the possibility that ordinary human metabolites may destabilize MRI contrast agents, amplifying the need for further investigation.
Crucially, our findings reveal a correlation between gadolinium retention and intracellular gadolinium-rich nanoparticles. This discovery paves the way for a fundamental understanding of the underlying mechanisms, necessitating rigorous investigation to inform and develop effective therapeutic interventions for patients with rare earth metal-induced illnesses, be they iatrogenic or environmentally induced. By unraveling the mysteries of gadolinium toxicity, we strive to contribute to the future development of rational therapies that prioritize patient well-being and safety.
Keywords: gadolinium, magnetic resonance imaging, adverse effect
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
